J. Hammermann

1.4k total citations
21 papers, 650 citations indexed

About

J. Hammermann is a scholar working on Pulmonary and Respiratory Medicine, Nutrition and Dietetics and Epidemiology. According to data from OpenAlex, J. Hammermann has authored 21 papers receiving a total of 650 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Pulmonary and Respiratory Medicine, 5 papers in Nutrition and Dietetics and 4 papers in Epidemiology. Recurrent topics in J. Hammermann's work include Cystic Fibrosis Research Advances (14 papers), Neonatal Respiratory Health Research (10 papers) and Tracheal and airway disorders (5 papers). J. Hammermann is often cited by papers focused on Cystic Fibrosis Research Advances (14 papers), Neonatal Respiratory Health Research (10 papers) and Tracheal and airway disorders (5 papers). J. Hammermann collaborates with scholars based in Germany, United States and Austria. J. Hammermann's co-authors include Joachim Kreuder, Reinald Repp, Arndt Borkhardt, Jochen Harbott, Oskar A. Haas, Fritz Lampert, Thomas Leis, Traudl Henn, Olaf Sommerburg and Ulrich Wahn and has published in prestigious journals such as Oncogene, Frontiers in Immunology and Allergy.

In The Last Decade

J. Hammermann

18 papers receiving 636 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
J. Hammermann Germany 11 237 197 168 167 91 21 650
Trudy M. Doyle United States 10 226 1.0× 210 1.1× 265 1.6× 11 0.1× 55 0.6× 14 626
Colton Smith United States 9 143 0.6× 17 0.1× 74 0.4× 18 0.1× 123 1.4× 19 516
Stephan Fasler Switzerland 10 78 0.3× 119 0.6× 395 2.4× 69 0.4× 133 1.5× 14 638
Farha El‐Chennawi Egypt 13 79 0.3× 16 0.1× 54 0.3× 19 0.1× 31 0.3× 24 385
Kimiko Kasahara Japan 11 126 0.5× 43 0.2× 92 0.5× 48 0.3× 44 0.5× 29 394
Heinz-Gerd Hoymann Germany 12 113 0.5× 132 0.7× 211 1.3× 86 0.5× 19 0.2× 17 522
Emmanuelle Henry Belgium 7 158 0.7× 115 0.6× 123 0.7× 37 0.2× 24 0.3× 7 700
Triin Laisk Estonia 17 137 0.6× 16 0.1× 49 0.3× 30 0.2× 9 0.1× 40 804
Tim Hunt United Kingdom 6 74 0.3× 59 0.3× 289 1.7× 235 1.4× 10 0.1× 9 583
K Kasahara Japan 12 104 0.4× 24 0.1× 97 0.6× 75 0.4× 30 0.3× 22 400

Countries citing papers authored by J. Hammermann

Since Specialization
Citations

This map shows the geographic impact of J. Hammermann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J. Hammermann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J. Hammermann more than expected).

Fields of papers citing papers by J. Hammermann

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J. Hammermann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J. Hammermann. The network helps show where J. Hammermann may publish in the future.

Co-authorship network of co-authors of J. Hammermann

This figure shows the co-authorship network connecting the top 25 collaborators of J. Hammermann. A scholar is included among the top collaborators of J. Hammermann based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J. Hammermann. J. Hammermann is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Hammermann, J., Manfred Ballmann, Lutz Nährlich, et al.. (2024). Mukoviszidose – wenn die Diagnose unsicher bleibt. Monatsschrift Kinderheilkunde. 172(6). 510–518.
2.
Schulte‐Hubbert, B., et al.. (2023). Chronic inhaled antibiotic therapy in people with cystic fibrosis with Pseudomonas aeruginosa infection in Germany. Pulmonary Pharmacology & Therapeutics. 80. 102214–102214. 1 indexed citations
3.
Prenzel, Freerk, Uta Ceglarek, J. Hammermann, et al.. (2021). Audit of sweat chloride testing reveals analytical errors. Clinical Chemistry and Laboratory Medicine (CCLM). 59(8). 1376–1383.
4.
Sommerburg, Olaf & J. Hammermann. (2020). Pancreatitis-Associated Protein in Neonatal Screening for Cystic Fibrosis: Strengths and Weaknesses. International Journal of Neonatal Screening. 6(2). 28–28. 7 indexed citations
5.
Ratjen, Félix, Alexander Mœller, Robert Maykut, et al.. (2018). Eradication of early P. aeruginosa infection in children <7 years of age with cystic fibrosis: The early study. Journal of Cystic Fibrosis. 18(1). 78–85. 28 indexed citations
6.
Kolenda, Rafał, Daniel C. Baumgart, Johann Pratschke, et al.. (2018). Mucosal Autoimmunity to Cell-Bound GP2 Isoforms Is a Sensitive Marker in PSC and Associated With the Clinical Phenotype. Frontiers in Immunology. 9. 1959–1959. 11 indexed citations
7.
Okuda, Kenichi, et al.. (2017). Treatment of high-grade osteoblastic osteosarcoma of the humerus in a 5-year-old boy with cystic fibrosis: A case report. Molecular and Clinical Oncology. 7(1). 148–150. 3 indexed citations
8.
Sommerburg, Olaf, Mirjam Stahl, J. Hammermann, et al.. (2017). Neugeborenenscreening auf Mukoviszidose in Deutschland: Vergleich des neuen Screening-Protokolls mit einem Alternativprotokoll. Klinische Pädiatrie. 229(2). 59–66. 11 indexed citations
9.
Stopsack, Konrad H., J. Hammermann, Olaf Sommerburg, et al.. (2016). A product of immunoreactive trypsinogen and pancreatitis-associated protein as second-tier strategy in cystic fibrosis newborn screening. Journal of Cystic Fibrosis. 15(6). 752–758. 15 indexed citations
10.
Sommerburg, Olaf, J. Hammermann, Martin Lindner, et al.. (2013). Comparison of different IRT-PAP protocols to screen newborns for cystic fibrosis in three central European populations. Journal of Cystic Fibrosis. 13(1). 15–23. 36 indexed citations
11.
Hammermann, J., et al.. (2012). WS21.2 Newborn screening for cystic fibrosis with an IRT-PAP protocol. Journal of Cystic Fibrosis. 11. S47–S47. 2 indexed citations
12.
Hammermann, J., et al.. (2011). 21* Improved cut off combination for IRT and PAP in newborn screening for cystic fibrosis. Journal of Cystic Fibrosis. 10. S6–S6. 1 indexed citations
13.
Hammermann, J., et al.. (2011). Improved cut off combination for IRT and PAP in Newborn Screening for Cystic Fibrosis. Clinical Biochemistry. 44(7). 545–545. 1 indexed citations
14.
Hammermann, J., et al.. (2009). Neonatal screening for cystic fibrosis: pros and cons.. Monatsschrift Kinderheilkunde. 157(12). 1222–1229.
15.
Hammermann, J., et al.. (2009). Neugeborenenscreening auf Mukoviszidose. Monatsschrift Kinderheilkunde. 157(12). 1222–1229. 5 indexed citations
16.
Rolinck‐Werninghaus, Claudia, Eckard Hamelmann, Thomas Keil, et al.. (2004). The co‐seasonal application of anti‐IgE after preseasonal specific immunotherapy decreases ocular and nasal symptom scores and rescue medication use in grass pollen allergic children. Allergy. 59(9). 973–979. 83 indexed citations
17.
18.
Borkhardt, Arndt, Reinald Repp, Oskar A. Haas, et al.. (1997). Cloning and characterization of AFX, the gene that fuses to MLL in acute leukemias with a t(X;11)(q13;q23). Oncogene. 14(2). 195–202. 212 indexed citations
19.
Repp, Reinald, et al.. (1995). Construction of RNA standards for high-resolution automatic product analysis in quantitative competitive RT-PCR.. PubMed. 19(1). 84, 86–8, 90. 18 indexed citations
20.
Repp, Reinald, Arndt Borkhardt, Joachim Kreuder, et al.. (1995). Detection of four different 11q23 chromosomal abnormalities by multiplex-PCR and fluorescence-based automatic DNA-fragment analysis.. PubMed. 9(1). 210–5. 69 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Trudy M. Doyle Breakdown of academic impact, for papers by Colton Smith Breakdown of academic impact, for papers by Stephan Fasler Breakdown of academic impact, for papers by Farha El‐Chennawi Breakdown of academic impact, for papers by Kimiko Kasahara Breakdown of academic impact, for papers by Heinz-Gerd Hoymann Breakdown of academic impact, for papers by Emmanuelle Henry Breakdown of academic impact, for papers by Triin Laisk Breakdown of academic impact, for papers by Tim Hunt Breakdown of academic impact, for papers by K Kasahara
Rankless by CCL
2026